Organic Letters · 2012 · 20 citations · 10 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyRadiobiologyAlkylating AgentsPositron Emission TomographyRadiopharmaceutical PreparationRadiopharmaceutical TherapyRadiopharmaceuticalsRadiotracer DevelopmentAlkylating Agent TherapyRadiochemical Purity AssessmentRadiochemical Purity SpecificationsRadiochemical SynthesisRadiochemical Yield DeterminationRadiotracer SynthesisTemozolomide Therapy
Temozolomide (TMZ) is a prodrug for an alkylating agent used for the treatment of malignant brain tumors. A positron emitting version, [(11)C]TMZ, has been utilized to help elucidate the mechanism and biodistribution of TMZ. Challenges in [(11)C]TMZ synthesis and reformulation make it difficult for routine production. A highly reproducible one-pot radiosynthesis of [(11)C]TMZ with a radiochemical yield of 17 ± 5% and ≥97% radiochemical purity is reported.
10
Temozolomide and treatment of malignant glioma.
Henry S. Friedman, Tracy Kerby, Hilary Calvert · PubMed · 2000 · 725 citations
Medicine, Oncology, Pharmacology +16
Brain tumor survival: Results from the National Cancer Data Base
Tanya Surawicz, Faith G. Davis, Sally Freels et al. · Journal of Neuro-Oncology · 1998 · 346 citations
Malcolm F. G. Stevens, John A. Hickman, Robert L. Stone et al. · Journal of Medicinal Chemistry · 1984 · 218 citations